山东医药2025，Vol.65Issue(3)：36-39,4.DOI:10.3969/j.issn.1002-266X.2025.03.008
恶性肿瘤患者围手术期应用贝伐珠单抗对输液港植入术术后并发症的影响
Effect of perioperative application of bevacizumab in patients with malignant tumors on postoperative complications after infusion port implantation
摘要
Abstract
Objective To observe the effect of perioperative application of bevacizumab in patients with malignant tumors on postoperative complications after infusion port implantation.Methods According to whether bevacizumab was used for anti-tumor angiogenesis therapy in perioperative period,139 patients with malignant tumor undergoing infusion port implantation were divided into the combined bevacizumab group(41 cases)and the simple treatment group(98 cas-es).All patients were followed up for more than 6 months.Postoperative complications of the two groups were recorded and compared,including early postoperative complications(≤30 d)and late postoperative complications(>30 d),and we calculated the incidence of postoperative complications.Results In the combined bevacizumab group,there was 1 case of poor wound healing,and the incidence of early complications was 2.44%.In the simple treatment group,hemor-rhage occurred in 4 cases and incision healing was poor in 1 case;the incidence of early postoperative complications was 5.10%.There were no significant differences in the incidence of early postoperative complications between the two groups(all P>0.05).In the combined bevacizumab group,there were 1 case of catheter obstruction and 1 case of infection,and the rate of late complications was 4.88%.In the simple treatment group,catheter displacement occurred in 2 cases,and the incidence of late complications was 2.04%.No significant differences were found in the incidence of late complications between the two groups(all P>0.05).Conclusion There is no significant effect of perioperative bevacizumab on postop-erative complications in patients with malignant tumors after infusion port implantation.关键词
围手术期/贝伐珠单抗/输液港植入术/术后并发症/恶性肿瘤/血管内皮生长因子Key words
perioperative period/bevacizumab/infusion port implantation/postoperative complications/malig-nant tumor/vascular endothelial growth factor分类
医药卫生引用本文复制引用
刘梅,穆宁,吴盛楠,徐悦,吕欢,王欣怡,马春华..恶性肿瘤患者围手术期应用贝伐珠单抗对输液港植入术术后并发症的影响[J].山东医药,2025,65(3):36-39,4.基金项目
中国健康促进基金会科研课题资助项目(2019ZGJCJJLM) （2019ZGJCJJLM）
天津市人民医院(南开大学第一附属医院)院内基金项目(2024YJ023). （南开大学第一附属医院）
